Jessica K Altman

Associate Professor, Medicine, Hematology Oncology Division

Phone312/503-1817
Emailj-altman@northwestern.edu

Source: Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Certifications and Licenses

	Medical Oncology
	Hematology
	Internal Medicine

Training Experience

2004	Residency, University of Chicago Hospitals
2007	Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MD, University of Pittsburgh

… → 2001

Research interests

Acute Leukemias
Anemia
Aplastic Anemia
Chronic Leukemias
Leukemia
Myelodysplastic Syndrome
Myeloproliferative Diseases
Targeted Therapies

Fingerprint

Dive into the research topics where Jessica K Altman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

18 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

17 Active
38 Finished

Prot #AT148002: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS)
Altman, J. K.
Novella Clinical, LLC, ALX Oncology, Inc
9/23/20 → 9/23/23
Project: Research project
Prot #IMGN632-0802: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Altman, J. K.
Precision Oncology, LLC, ImmunoGen, Inc.
6/4/20 → 6/4/23
Project: Research project
Prot #20170528: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Altman, J. K.
Amgen, Inc.
6/3/20 → 6/3/23
Project: Research project
Prot #KRT-232-104: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)
Altman, J. K.
INC Research, LLC, Kartos Therapeutics, Inc.
2/5/20 → 2/5/23
Project: Research project
Prot #PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Altman, J. K.
Alpha Oncology, Inc., PrECOG, LLC
1/30/20 → 1/30/23
Project: Research project

5971 Citations
84 Article
27 Review article
9 Comment/debate
4 Letter
More
- 2 Chapter

American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Sekeres, M. A., Guyatt, G., Abel, G., Alibhai, S., Altman, J. K., Buckstein, R., Choe, H., Desai, P., Erba, H., Hourigan, C. S., LeBlanc, T. W., Litzow, M., MacEachern, J., Michaelis, L. C., Mukherjee, S., O'Dwyer, K., Rosko, A., Stone, R., Agarwal, A., Colunga-Lozano, L. E. & 3 others, Chang, Y., Hao, Q. K. & Brignardello-Petersen, R., Aug 11 2020, In: Blood Advances. 4, 15, p. 3528-3549 22 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
3 Scopus citations
Chronic myeloid leukemia, version 2.2021
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., Mead, M., Metheny, L., Mohan, S., Moore, J. O., Naqvi, K., Oehler, V., Pallera, A. M., Patnaik, M., Pratz, K., Pusic, I. & 9 others, Rose, M. G., Smith, B. D., Snyder, D. S., Sweet, K. L., Talpaz, M., Thompson, J., Yang, D. T., Gregory, K. M. & Sundar, H., Oct 2020, In: JNCCN Journal of the National Comprehensive Cancer Network. 18, 10, p. 1385-1415 31 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
COVID-19 and Cancer Consortium, Jun 20 2020, In: The Lancet. 395, 10241, p. 1907-1918 12 p.
Research output: Contribution to journal › Article › peer-review
215 Scopus citations
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Roboz, G. J., DiNardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., Mannis, G. N., Pollyea, D. A., Stein, A. S., Uy, G. L., Watts, J. M., Fathi, A. T., Kantarjian, H. M., Tallman, M. S., Choe, S., Dai, D. & 11 others, Fan, B., Wang, H., Zhang, V., Yen, K. E., Kapsalis, S. M., Hickman, D., Liu, H., Agresta, S. V., Wu, B., Attar, E. C. & Stone, R. M., Feb 13 2020, In: Blood. 135, 7, p. 463-471 9 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
30 Scopus citations
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Choe, S., Wang, H., DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Watts, J. M., Pollyea, D. A., Fathi, A. T., Tallman, M. S., Kantarjian, H. M., Stone, R. M., Quek, L., Konteatis, Z., Dang, L., Nicolay, B., Nejad, P., Liu, G. & 9 others, Zhang, V., Liu, H., Goldwasser, M., Liu, W., Marks, K., Bowden, C., Biller, S. A., Attar, E. C. & Wu, B., May 12 2020, In: Blood Advances. 4, 9, p. 1894-1905 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
12 Scopus citations